Premium
Lessons from Two Trials of Mycophenolate Mofetil in Myasthenia Gravis
Author(s) -
Sanders Donald B.,
Siddiqi Zaeem A.
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1405.031
Subject(s) - mycophenolate , myasthenia gravis , clinical trial , medicine , population , randomized controlled trial , intensive care medicine , transplantation , environmental health
Two randomized controlled trials of mycophenolate mofetil (MMF) in the treatment of myasthenia gravis (MG) were recently completed. Although neither study demonstrated efficacy of MMF in the population of patients studied, there are valuable lessons in the way these studies were developed and performed. After reviewing the design and results of these trials, we discuss possible reasons leading to negative results and the lessons learned, which should be useful for future clinical trials in MG.